Claritas Pharmaceuticals Inc. (V:CLAS)
Business Focus: Biotechnology & Medical Research (NEC)
Jul 20, 2022 07:48 am ET
IIROC Trading Halt - CLAS
VANCOUVER, BC, July 20, 2022 /CNW/ - The following issues have been halted by IIROC:
Apr 26, 2022 12:10 pm ET
IIROC Trading Halt - CLAS.WT.B
VANCOUVER, BC, April 26, 2022 /CNW/ - The following issues have been halted by IIROC:
Apr 07, 2022 07:30 am ET
Claritas Announces Approval from OTC to Up-List to OTCQB
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") is pleased to announce that it has obtained approval from the OTC Markets Group for listing of its Common Shares on the OTCQB. The Company will...
Apr 05, 2022 07:15 am ET
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced that the Australian Human Research Ethics Committee has approved the Company’s submission for the Phase 1 clinical study of...
Feb 22, 2022 07:30 am ET
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has received comments from the Australian Human Research Ethics Committee (the “HREC”) regarding the Company’s Phase 1 clinical...
Feb 09, 2022 07:15 am ET
Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16th to review the submission made by the Company for...
Jan 26, 2022 05:50 pm ET
Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced revised, improved pricing for the initial tranche of funds that the Company will receive under its equity financing agreement (the...
Jan 17, 2022 07:30 am ET
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns
Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has signed a Letter of Intent dated January 17, 2022 (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman...
Jan 17, 2022 07:00 am ET
Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced the Company’s new registered and records office address, confirmed its management and Board of Directors and announced the terms of the...
Jan 12, 2022 01:23 pm ET
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has entered into an agreement (the “Agreement”) with Alumina Partners (Ontario) Ltd. (“Alumina”), an affiliate of Alumina...
Jan 04, 2022 07:30 am ET
Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications. Claritas’...
Dec 22, 2021 07:15 am ET
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it will develop R-107 for the treatment of persistent pulmonary hypertension of the newborn (“PPHN”). PPHN is fatal in up to 50%...
Dec 21, 2021 07:15 am ET
Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into a License Amendment dated December 17, 2021 (the “License Amendment”) under which Salzman Group, Inc. (a...
Dec 20, 2021 07:15 am ET
Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the journal Scientific Reports, has published a peer-reviewed article reporting that R-107, the Company’s nitric oxide-releasing...
Nov 18, 2021 07:15 am ET
Claritas Provides Update Regarding Phase 1 Clinical Study
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today provided an update regarding the expected time to completion of its Phase 1 clinical study of R-107, the Company’s proprietary, liquid, nitric...
Nov 04, 2021 07:15 am ET
Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced the engagement of B. Riley Securities, Inc. (“B. Riley Securities”) as its exclusive capital markets advisor with respect to the...
Oct 19, 2021 07:15 am ET
Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") is pleased to announce that it has closed the first tranche of a private placement offering (the “Offering”) of convertible debentures with Obsidian...
Sep 16, 2021 07:15 am ET
Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced that it has entered into a binding Letter of Intent (the “LOI”) with Biozeus Biopharmaceuticals S. A., a Brazilian corporation...
Aug 18, 2021 01:12 pm ET
IIROC Trading Resumption - CLAS
VANCOUVER, BC, Aug. 18, 2021 /CNW/ - Trading resumes in:
Aug 18, 2021 12:52 pm ET
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the "Company" or "Claritas") is pleased to announce that, subject to TSXV approval, it will close the first tranche of a brokered private placement offering (the “Offering”) of...
Aug 18, 2021 11:53 am ET
IIROC Trading Halt - CLAS
VANCOUVER, BC, Aug. 18, 2021 /CNW/ - The following issues have been halted by IIROC:
Aug 09, 2021 12:14 pm ET
IIROC Trading Halt - CLAS.WT.A
VANCOUVER, BC, Aug. 9, 2021 /CNW/ - The following issues have been halted by IIROC:
Jul 27, 2021 07:55 pm ET
Claritas Announces Grant of Stock Options to Directors and Officers
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") announced that it granted stock options on July 23, 2021 to the directors and officers of the Company. The stock options have an exercise price...
Jul 26, 2021 07:15 am ET
Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust1 validates the potential of the...
Jul 21, 2021 07:15 am ET
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to provide additional detail regarding exceptionally positive data with R-107 in a validated animal model of pulmonary arterial hypertension...
Jul 20, 2021 05:04 pm ET
Claritas Announces Effective Date for Share Consolidation
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce that the previously disclosed consolidation of its Common Shares (the "Consolidation") has received final approval from...
Jun 10, 2021 07:15 am ET
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has received commitments from the Company’s two largest shareholders to vote in favor of the special resolution to...
Jun 01, 2021 07:15 am ET
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into an agreement (the “Debt Forgiveness Agreement”) with the former shareholders of Talent Biotechs Ltd....
May 11, 2021 08:30 am ET
Claritas Pharmaceuticals Issues Letter to Shareholders
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the “Company” or “Claritas”) today issued the following letter to shareholders from Robert Farrell, the Company’s President and CEO. Dear Fellow Shareholders,...
Apr 21, 2021 05:00 am ET
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd (“CMAX”) to conduct a randomized, placebo-controlled,...
Apr 14, 2021 01:51 pm ET
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd....
Apr 08, 2021 08:15 am ET
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that, based on significantly positive results in a controlled large animal model of sepsis, the Company will now expand its R-107...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
